Calcium

Human medicines European public assessment report (EPAR): Yorvipath, Palopegteriparatide, Date of authorisation: 17/11/2023, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Gland, Medical Subject Headings, Marketing, INN, ATC, EMA, International, Parathyroid hormone, Headache, Needle, Disease, Language, Blood, Calcium, Teriparatide, PTH, Heart, Pseudohypoparathyroidism, European Medicines Agency, EMEA, Select, Patient, Diagnosis, Anatomy, Paresthesia, IIA, Neck, Skin, Medical device

Hypoparathyroidism is rare, and Yorvipath was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 October 2020.

Key Points: 
  • Hypoparathyroidism is rare, and Yorvipath was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 October 2020.
  • Teriparatide replaces the missing hormone in patients with hypoparathyroidism, acting through bone tissue and the kidneys to help restore calcium levels.
  • The European Medicines Agency therefore decided that Yorvipath’s benefits are greater than its risks and it can be authorised for use in the EU.
  • Yorvipath : EPAR - Medicine overview
    Product information
    Yorvipath : EPAR - Product information
    Latest procedure affecting product information: EMEA/H/C/005934
    This medicine’s product information is available in all official EU languages.

Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Risk, Woman, Hypercalcaemia, Menopause, Man, Cancer, Avascular necrosis, Risk management, Anatomy, Female, IIA, Osteitis, Jaw, Osteoclast, CHMP, Fever, Fracture, ATC, Pain, European, Disease, Calcium, Kidney, Paget's disease, Glucocorticoid, Neoplasm, Arthralgia, Hypocalcemia, Patient, Medical Subject Headings, Hip, Trauma, European Commission, Vitamin D, International, Language, Mouth, Select, Medicine, Paget's disease of bone, Allergy, Headache, Ibuprofen, Spine, Myalgia, Committee, Cell, Necrosis, Dietary supplement

Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 17, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Gland, Medical Subject Headings, Diarrhea, Urine, Marketing, European Commission, Agency, INN, Risk, Vitamin D, ATC, System, International, European, Headache, Disease, Needle, Osteosarcoma, Hypoesthesia, Blood, Language, Calcium, Heart, Cancer, Pseudohypoparathyroidism, European Medicines Agency, Thigh, Select, Safety, Kidney, Anatomy, Medicine, Paresthesia, Vomiting, IIA, Neck, Skin, Medical device

Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 17, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 17, Status: Authorised

Tenth Study Demonstrates Good Health in Vegan Dogs

Retrieved on: 
Thursday, November 9, 2023
Quality of life, Pet, X-ray, Vitamin D, Meat, WINCHESTER, Fed, Cat, Animal welfare, Health, Vegetarianism, Blood, Calcium, Dog, Greenhouse, Animal, Nutrition, Water, Ontario Veterinary College, Nutrients (journal), Knight, Animal feed

And now a study just published in the British Journal of Nutrition has demonstrated good health outcomes in dogs fed vegan diets.

Key Points: 
  • And now a study just published in the British Journal of Nutrition has demonstrated good health outcomes in dogs fed vegan diets.
  • Dr Sarah Dodd and other veterinary nutritional specialists from Canada's Ontario Veterinary College found that 31 dogs fed vegan diets for three months had health outcomes as good as 30 fed meat-based diets.
  • This is the latest among 10 studies that have now confirmed good health outcomes in dogs fed vegan diets.
  • In 2002 Prof. Knight and colleagues also studied health outcomes in 2,536 dogs and concluded that the healthiest and least hazardous diets for dogs were nutritionally sound vegan diets.

BonnEarth Celebrates Diversity with Launch of Halal-Certified Multivitamins for Kids

Retrieved on: 
Thursday, November 30, 2023
Family, Research, QR, Amazon, Taste, Parent, Calcium, Breakfast, Halal, Growth, Iron, Child, Dietary supplement

BonnEarth, a 100% women- and minority-owned business, was founded by a team of pharmaceutical and nutraceutical professionals who are all ingredients nerds.

Key Points: 
  • BonnEarth, a 100% women- and minority-owned business, was founded by a team of pharmaceutical and nutraceutical professionals who are all ingredients nerds.
  • It can be challenging to ensure our kids get the best options on the market," says Sanobar S. Abdi, the founder of BonnEarth.
  • With the successful launch of its supplements for children, BonnEarth is now focusing on 2024.
  • We will leave no stone unturned in our mission to deliver high-quality vegetarian and Halal-nutrition to adults and kids of all ages."

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Retrieved on: 
Wednesday, December 6, 2023
Quality of life, CYP, Kidney, Risk, Heartburn, Enzyme inhibitor, FDA, TIN, Hypertension, Achlorhydria, Magnesium, Liver, PPI, SJS, Magnesium deficiency, Chest pain, Atazanavir, Endoscopy, Impairment, SCAR, Vitamin B12, Malabsorption, Absorption, PDUFA, CDAD, Calcium, New Drug Application, Gastritis, Enzyme, Food and Drug Administration, Clostridioides, Vonoprazan, Patient, Hip, Hypokalemia, Food, Polyp, GERD, Nelfinavir, Toxicity, EGFR, Wrist, Diarrhea, Hypocalcemia, NDA, Abdominal pain, Urinary tract infection, Hypersensitivity, Stevens–Johnson syndrome, Glomus tumor, Spine, Indigestion, Drug, CGA, Lactation, Pharmaceutical industry

The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.

Key Points: 
  • The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.
  • “Non-Erosive GERD represents a substantial segment of the U.S. GERD population, affecting millions of individuals and impacting their quality of life.
  • Symptoms impact overall quality of life and can include episodic heartburn, especially at night, regurgitation, problems swallowing, and chest pain.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.

4 Signs You Need to Treat the Water in Your Home

Retrieved on: 
Monday, December 4, 2023
Lead, Smell, Water, PFOA, Mineral, Irritation, Skin, Health, Electricity, Culligan, Calcium, Filtration, Sulfate, Organic compound, Clothing, Volatile organic compound, Safety, PFAS, Bacteria, Arsenic, Bicarbonate, Bottled water

Water contamination can happen through a local municipality’s water source, an underground well or a homeowner’s pipes.

Key Points: 
  • Water contamination can happen through a local municipality’s water source, an underground well or a homeowner’s pipes.
  • A water test will be able to detect harmful chemicals and help determine what water treatment solution is needed to remove the contaminants.
  • Culligan’s Aquasential® Smart High Efficiency (HE) Water Softener offers high-efficiency water softening for your home and is regarded as the world’s most efficient water softener***.
  • Since your home’s pipes are constantly in contact with your water, water that contains harmful impurities can lead to damage in your home’s plumbing system.

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Retrieved on: 
Tuesday, November 28, 2023
HIV-1, Risk, Heartburn, MOA, Enzyme inhibitor, Potassium, FDA, Magnesium, Nausea, PPI, Inflammation, Prescription, Esophagus, Bone fracture, Skin, Chills, Extrapyramidal system, Fever, Vitamin, Breast milk, Infection, Diarrhea, Helicobacter pylori, Indigestion, Bleeding, Disease, Muscle weakness, Tongue, Calcium, Acid, University, Human, Pharmacy, Clostridioides, Vonoprazan, Urine, Hip, B-12, Food, Polyp, Esophagitis, GERD, Chronic pain, Blood, Dizziness, Blister, Gastroesophageal reflux disease, Tablet, Vitamin B12, Scar, Patient, Wrist, Medicine, Seizure, HIV, Stomach, Lymph, Allergy, Clostridioides difficile, Rash, Weakness, Urinary tract infection, Hypoesthesia, Week, Myalgia, Spine, Spasm, Kidney, Face, Rilpivirine, Lansoprazole, Pharmaceutical industry

“We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.

Key Points: 
  • “We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.
  • “Erosive GERD is a highly prevalent condition affecting over 20 million people in the U.S.,3,4 many of whom experience troubling symptoms, including painful heartburn.
  • Phathom is offering programs for eligible patients who face coverage or affordability issues, including co-pay assistance for patients with commercial insurance.
  • for up to 6 months to maintain healing of Erosive Acid Reflux and for relief of heartburn related to Erosive Acid Reflux.

Standard Lithium Provides Comprehensive Results of Its Fully Optimized and Proven DLE Process

Retrieved on: 
Monday, November 20, 2023
Lithium, Dorado, Plant, DLE, Demonstration plant, Potassium, Magnesium, LSS, FRA, Calcium, Knowledge, SLI, Lithium chloride, Boron, Sodium

EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.

Key Points: 
  • EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.
  • Standard Lithium's Demonstration Plant is the only truly large-scale, continuously operating DLE plant in North America.
  • Both studies incorporate the LiPROTM LSS (DLE) process developed in collaboration with Koch Technology Solutions, LLC (“KTS”).
  • Lithium Recovery Efficiency: During a representative period of performance over July and August 2023, the LiPROTM LSS (DLE) process achieved an average lithium recovery of 96.1% from the continuous incoming brine flow.

Standard Lithium Provides Comprehensive Results of Its Fully Optimized and Proven DLE Process

Retrieved on: 
Monday, November 20, 2023
Lithium, Dorado, Plant, DLE, Demonstration plant, Potassium, Magnesium, LSS, FRA, Calcium, Knowledge, SLI, Lithium chloride, Boron, Sodium

EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.

Key Points: 
  • EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.
  • Standard Lithium's Demonstration Plant is the only truly large-scale, continuously operating DLE plant in North America.
  • Both studies incorporate the LiPROTM LSS (DLE) process developed in collaboration with Koch Technology Solutions, LLC (“KTS”).
  • Lithium Recovery Efficiency: During a representative period of performance over July and August 2023, the LiPROTM LSS (DLE) process achieved an average lithium recovery of 96.1% from the continuous incoming brine flow.